AbbVie Inc. stock gains on new AI drug discovery collaboration with Iambic

Published on 09/21/2026 at 15:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie Inc. stock trades around USD 263 on September 21, 2026, close to its 52-week high after announcing a multi-year AI drug discovery deal with Iambic. The company reported strong double-digit revenue growth in Q2 2026, supporting its dividend profile.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. stock (ISIN US00287Y1091) is changing hands at around USD 263.52 on Nasdaq on September 21, 2026, keeping the shares within sight of their 52-week high of USD 267.47 as investors digest a fresh AI drug discovery collaboration announcement. Per a company press release dated September 21, 2026, AbbVie has entered a multi-year partnership with Iambic to apply artificial intelligence to small molecule drug discovery across immunology, neuroscience and oncology.

AI collaboration underpins growth ambitions

According to Yahoo Finance on September 21, 2026, AbbVie and Iambic have agreed a multi-year collaboration that will harness Iambic's AI-driven discovery and development platform to accelerate the identification of first-in-class and best-in-class small molecule therapies in AbbVie focus areas including immunology, neuroscience and oncology.

As Investing.com reports on September 21, 2026, the agreement is described as a multi-year collaboration that will apply artificial intelligence to small molecule drug discovery, underscoring AbbVie's intent to deepen its pipeline in key therapeutic franchises and to use digital tools to compress discovery timelines.

Recent financial performance and dividend context

For investor context, AbbVie reported double-digit revenue growth in its most recent quarterly update for Q2 2026, with total revenue rising versus the prior-year period as the company continued to transition beyond its legacy Humira franchise and scale newer assets such as Skyrizi and Rinvoq; this Q2 2026 comparison frames how the pipeline-focused AI deal aims to sustain that growth trajectory.

AbbVie is also widely followed for its status as a dividend payer, and portals tracking the stock highlight a dividend yield around 2.59 percent based on the current share price and recent dividend distributions, reinforcing the balance between growth investment and shareholder returns.

Stock near the top of its 52-week range

Per Robinhood quote data for September 21, 2026, AbbVie stock traded at USD 263.52 on Nasdaq during the session, within a daily range that saw an intraday low of USD 262.06 and a high of USD 266.34, and modestly above the 52-week low of USD 190.75 while still below the 52-week high of USD 267.47.

According to Robinhood, the same snapshot shows a market capitalization of about USD 466.34 billion for AbbVie, with trading volume around 8.18 million shares relative to an average daily volume near 4.73 million shares, indicating heightened interest around the AI collaboration and the broader pipeline narrative.

Closing price and investor takeaway

AbbVie Inc. stock most recently closed near USD 263.52 on Nasdaq as of September 21, 2026, leaving the shares just a few dollars below their 52-week high of USD 267.47 and reflecting how the market is currently pricing the combination of a growing pipeline, ongoing dividend payments and new AI-driven discovery initiatives.